Neurocrine Biosciences | NBIX - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 29.06B 523M 2025-12
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
ALKERMES USD 1.36B 570.52M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Cytokinetics USD 839.46M 77.51M 2026-03
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Exelixis USD 1.44B 41.03M 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Incyte USD 5.48B 460.36M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Pfizer USD 42.82B 76M 2026-03
Prothena USD 315.19M 24.78M 2025-12
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Repligen USD 1.14B 40.9M 2025-12
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Teva Pharmaceutical Industries USD 13.71B 236M 2026-03
Ultragenyx Pharmaceutical USD 951M 307.79M 2025-12
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03
Xoma USD 110.71M 5.78M 2025-09